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Abstract
Background: A neuroendocrine tumor (NET) can develop anywhere in the body, but is mainly found in the
pancreas, gastrointestinal tract, and lungs. This report is a retrospective study of the clinicopathological features of
NET patients with brain metastasis whose tissue diagnosis was made at our hospital.
Methods: Patients with brain metastasis evidenced by clinical records and images were accumulated among 302
patients in whom tissue diagnosis of NETs was made at our hospital between 2008 and 2013. In the patients, the
primary lesion, pathological classification, pattern of metastasis, details of treatment, and outcomes were analyzed.
Results: Brain metastasis was observed in 31 patients (10.3 %). The primary lesion was in the lungs in 26 patients
(83.9 %), and the mammary glands, esophagus, and uterus in 1 patient each. Primary lesions were unknown in 2
patients, including 1 patient in whom NETs were detected in the lymph nodes alone. Pathological classification of
the primary lesion was NET Grade 2 (Ki-67: 3 to 20 %) in 3 patients and neuroendocrine carcinoma (NEC, Ki-67:
≥21 %) in 26 patients. The median period from onset of the primary lesion up to diagnosis of brain metastasis was
12.8 months, and the brain lesion preceded brain metastasis in 6 patients. Ten patients had a single metastasis
whereas 21 patients had multiple metastases, but no characteristics were observed in their images. Brain metastasis
was extirpated in 10 patients. Stereotactic radiotherapy alone was administered in 6 patients, and brain metastasis
was favorably controlled in most of the patients with coadministration of cranial irradiation as appropriate. The
median survival period from diagnosis of brain metastasis was 8.1 months, and the major cause of death was
aggravation of the primary lesion or metastatic lesions in other organs.
Conclusion: Most of NET patients with brain metastasis showed the primary lesion of NEC in the lungs, and they
had multiple metastases to the liver, lymph nodes, bones, and so forth at the time of diagnosis of brain metastasis.
The guidelines for accurate diagnosis and treatment of NETs should be immediately established based on further
analyses of NET patients with brain metastasis.
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Background
A neuroendocrine tumor (NET) is characterized by pro-
duction and secretion of peptide hormones, amines, or
the presence of secretory granules. The term “carcinoid”
was used for a long time because patients with a primary
lesion in the gastrointestinal tract were mainly examined
and the course was relatively favorable [1].
However, recent research has shown that NETs are
not limited to the gastrointestinal tract and originate
from dispersed endocrine cells that are widely distrib-
uted all over the body. They develop in all organs, and
there are not only patients who present a favorable
clinical pathology, but many of them also have a ma-
lignant course. The World Health Organization (WHO)
therefore attempted to grade NETs based on systematic
clinical pathological classification, but classifications with
different criteria were proposed for NETs originating from
the favored sites (pancreas and gastrointestinal tract) and
NETs originating from the lungs. Discussions are still
continuing concerning the validity of each classification
and establishment of standard criteria, but a standard
pathological entity is not yet available.
With advances in pathological diagnosis of NETs, neu-
rosurgeons are increasingly experiencing patients with
brain metastasis from tumors diagnosed as NETs [2–7].
However, few reports examined brain metastasis of NET
patients [2] and therefore, guidelines should be prepared
for oncologists based on findings from clinical images
and pathology as well as treatment and outcomes of
brain metastasis of NETs, and then taking appropriate
measures.
We accumulated cases of NET patients with brain
metastasis at our hospital and performed clinical patho-
logical analysis. The results are reported below.
Methods
The terms related to NETs, including “carcinoid”, “endo-
crine”, “neuroendocrine”, “small cell carcinoma” and “large
cell neuroendocrine carcinoma (LCNEC)”, were searched
among histopathological diagnoses of all neoplasm speci-
mens obtained during surgical procedures at Tokyo
Medical University Hospital during the 6 years between
January 2008 and December 2013. As a result, 302 pa-
tients were confirmed carrying a diagnosis of NETs. The
diagnoses consisted of carcinoid in 75 patients, endocrine
in 47 patients, neuroendocrine in 149 patients, small cell
carcinoma in 30 patients, and LCNEC in 26 patients. They
also included duplications of search terms, and final
diagnosis of LCNEC or small cell carcinoma following the
initial diagnosis of carcinoma with neuro-endocrine differ-
entiation. The age of patients ranged between 21 and
91 years (median: 64.5 years old), and there were 182
men and 120 women. The primary site of NETs was the
lungs in 103 patients, rectum in 37 patients, pancreas in
26 patients, stomach in 20 patients, mammary glands in
20 patients, uterus in 18 patients, lymph nodes in 17 pa-
tients, and duodenum in 12 patients. Other sites of onset
were the thymus gland in 8 patients, esophagus in 6
patients, ileum in 5 patients, liver in 5 patients, colon in 3
patients, pharynx in 3 patients, paranasal sinus in 3
patients, kidneys in 2 patients, urinary tract in 2 patients,
and ovaries in 2 patients.
We then searched medical charts and imaging findings
of the 302 patients carrying a diagnosis of NETs and
extracted 31 patients (10.3 %) in whom brain metastasis
was diagnosed based on either medical charts or imaging
findings. In the 31 patients, their clinical images, primary
lesion, pathological diagnosis, imaging findings, treat-
ment, and outcomes were retrospectively analyzed.
This study was conducted in accordance with the
Helsinki Declaration and was approved by the Ethical
Review Board of Tokyo Medical University Hospital.
Each patient signed a written informed consent form
that was approved by our institutional Committee on




The age of the 31 patients ranged between 34 and 78 years
(median: 68 years old) and 19 of them were men and 12
of them were women.
The primary lesion in 6 patients (19.4 %) was detected
by close examination after hospitalization following the
onset of intracranial hypertension, disorientation, or local
neurological symptoms such as paralysis and cerebellar
symptoms, due to brain metastasis. The primary lesion
remained unknown in 1 patient in spite of repeated close
systemic examinations.
Of the remaining 25 patients in whom brain metasta-
sis was diagnosed during treatment of the primary le-
sion, brain metastasis was confirmed in 17 patients by
imaging, which was performed due to the occurrence of
local neurological symptoms or intracranial hyperten-
sion, whereas 8 patients did not show definite neuro-
logical symptoms and brain metastasis was confirmed by
imaging screening. The period from definitive diagnosis of
primary lesion up to confirmation of brain metastasis
ranged between 0 and 33.4 months (median: 12.8 months)
(Fig. 1).
Primary lesion and pathological diagnosis
The primary lesion was in the lungs in 26 (83.9 %) of 31
patients. Other organs containing the primary lesion in-
cluded the mammary glands, esophagus, and uterus in 1
patient each, and unknown in 2 patients, including 1 pa-
tient in whom NETs were detected in the lymph glands
alone. The final pathological diagnosis of lung NETs was
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large cell neuroendocrine carcinoma (LCNEC) in 10 pa-
tients, small cell carcinoma in 10 patients, and carcin-
oma with neuroendocrine differentiation in 6 patients.
The patient with the primary lesion in the mammary
glands was diagnosed as having adenocarcinoma with
neuroendocrine differentiation, the patient with the pri-
mary lesion in the esophagus as having squamous cell
carcinoma with neuroendocrine differentiation, and the
patient with the primary lesion in the uterus as having
LCNEC. A diagnosis of small cell carcinoma was made in
the patients with no primary lesion other than in the
lymph nodes or with an unknown primary lesion. Accord-
ing to the grading by the percentage of Ki-67 positively
stained cells, 3 patients (all of them had NETs originating
from the lungs) were Grade 2 (Ki-67: 3 to 20 %) and 28
patients (90.3 %) were Grade 3 (Ki-67: ≥20 %).
Imaging diagnosis (Fig. 2)
As a result of examination of patterns of metastasis by
contrast-enhanced T1-weighted MRI, 7 patients were
classified as having the single/nodular type, 3 patients as
having the single/cystic type, 10 patients as having the
multiple/nodular type, 3 patients as having the multiple/
cystic type, and 8 patients as having the multiple/nodular
and cystic type. Therefore, no unique imaging patterns
characteristic of NET patients with brain metastasis were
observed. All the patients demonstrating single brain me-
tastasis had NETs originating from lung, but the patients
from non-lung (breast, esophagus, uterus, lymph node)
NETs demonstrated multiple brain metastases.
Treatment
When onset of brain metastasis was confirmed, optimal
therapy was chosen and performed based on compre-
hensive evaluation of the age, performance status (PS),
imaging findings, and clinical course of the primary
lesion. The lesion that caused symptoms was extirpated
as completely as possible in principle, and postoperative
cranial irradiation or stereotactic radiotherapy was con-
comitantly performed as necessary. Details of treatment
varied with each patient. For example, the gamma knife
was used for a lesion with 3 or fewer small tumors to
alleviate symptoms, and cranial radiotherapy alone for a
lesion with 4 or more tumors. In addition, treatment
was switched to best supportive care at the onset of
brain metastasis due to poor PS caused by lesions in
other organs. Eventually, the main treatments included
craniotomy plus cranial irradiation in 7 patients, cranial
irradiation alone in 11 patients, and gamma knife alone
in 6 patients.
Outcomes
The follow-up period after treatment of metastatic brain
tumors was from 1 to 34 months (median: 5.8 months),
and 29 of 31 patients were deceased by the time of
completion of examinations. Analysis by the Kaplan-
Meier survival curve revealed a median survival period
of 8.1 months (Fig. 3). Of the 29 deceased patients, only
Table 1 Clinical pathological images of a patient with brain
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LCNEC 11 (35.5 %)
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Multiple/nodular and cystic type 8
Treatment
Surgery 2
Surgery + WBRT 7
Surgery + GK 1
Surgery + WBRT + GK 1
WBRT 11
GK 6
WBRT + GK 1
Chemotherapy 1
Best supportive care 1
N number, LCNEC large cell neuroendocrine tumor, WBRT whole brain
radiotherapy, GK gamma knife
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1 patient died due to central nervous system symptoms
caused by uncontrollable brain metastasis. The other
patients died because of aggravation of their general
condition due to the primary lesion or metastasis to the
liver, adrenal gland, lymph nodes, or bones (including
the spine), observed at the time of confirmation of brain
metastasis. Both of the patients who survived until com-
pletion of examinations had the primary lesion in the
lungs. Of these 2 patients, 1 patient who was on chemo-
therapy due to poorly differentiated carcinoma with
neuroendocrine differentiation of the single/nodular type
was favorably controlled for 34 months with the gamma
knife. The other patient who was on chemotherapy for
LCNEC developed brain metastasis of the multiple/
nodular type, but was favorably controlled for 10 months
by the gamma knife.
Presentation of typical cases
 A patient with no notable medical history and no
history of smoking presented with an abnormal
shadow of the chest detected at a medical checkup.
A pulmonary CT scan showed a small lesion on the
mediastinum at the right S2 (Fig. 4a). The result of
transbronchoscopic lung biopsy (TBLB) led to the
diagnosis of LCNEC. Contrast-enhanced head MRI
was conducted because he presented with headache,
diplopia, and disorientation during maintenance
chemotherapy with cisplatin and CPT-11
(camptothecin 11). A solid tumor was observed
in the pineal body, together with obstructive
hydrocephalus. A nodular tumor was observed in
the cerebellar parenchyma in the vicinity of the
superior medullar velum, which was diagnosed as a
metastatic brain tumor of the multiple/nodular type
11.7 months after the pathological diagnosis of the
lungs (Fig. 4b). Biopsy for the pineal body tumor
and a third ventriculostomy for hydrocephalus were
performed by neuroendoscopy. The isolated tissues
were comprised of a dense proliferation of large
epithelial tumor cells with severe necrotic
degeneration, and synaptophysin and chromogranin
G were positive and diffused in the cytoplasm. The
percentage of Ki-67 positive cells was 35 % and the
patient’s lesion was diagnosed as brain metastasis





















Fig. 1 Period from tissue diagnosis of the primary neuroendocrine tumor until diagnosis of brain metastasis in 31 patients
A  B C D
Fig. 2 Imaging diagnosis patterns. a single/nodular type. b single/cystic type. c multiple/nodular type. d multiple/cystic type
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patient complained of pain in the posterior cervical
region, weakness in the arms, and paresthesia after
postoperative cranial irradiation at 30 Gy, and close
examination showed metastasis to the cervical
vertebra at C3, and the vertebral body and vertebral
arch at C6 and C7 (Fig. 4g). Neither the patient nor
his family wished to continue treatment. Therefore,
the patient was switched to best supportive care at
2.9 months after brain surgery, and died 1 month
later due to respiratory failure caused by rapid
enlargement of pulmonary lesions.
 A patient with no notable medical history and no
history of smoking visited our hospital with a
complaint of sudden onset of left hemiplegia.
Contrast-enhanced head MRI showed multiple
tumors with cysts in the right posterior lobe and the
parietal lobe (Fig. 5a, b). The tumor in the right
parietal lobe was considered to be the cause of the
hemiplegia. Therefore, craniotomy was conducted
for total resection of the tumor. He received
postoperative cranial irradiation at 30 Gy and
received ambulatory discharge. Images revealed
isolated tissues comprised of pattern-less dense
proliferation of small spindle-shaped tumor cells.
The cytoplasm of tumor cells was strongly positive
for synaptophysin, CD56, TTF1, and CK7 (Fig. 5c-f ).
Small cell carcinoma originating from the lungs was
suspected, although the primary lesion was not
identified in spite of examinations by contrast-
enhanced whole-body CT scan, gallium scintigraphy,
ultrasonography of the thyroid gland and the
abdomen, endoscopy of the upper and lower
gastrointestinal tract, and whole-body FDG-PET.
The brain tumors were favorably controlled in the
meantime and PS was maintained at 0 or 1 (Fig. 5g, h).
However, generalized malaise rapidly increased at
around 14 months after brain surgery and the patient
died 16 months after surgery while receiving
treatment at home. The primary lesion remained
unknown.
Discussion
In 1907, NETs in the small intestine were described as
“carcinoid” by Oberndorfer, because the clinical course
was relatively favorable and they were pathologically
differentiated [1]. Since then, carcinoid has been the
description of the disease group for more than 90 years.
It was later considered that NETs should be treated as
clinically malignant tumors and the term “carcinoid” was
eliminated from the WHO classification in 2000. Sub-
sequently, NETs were categorized into five types, namely
NET Grade 1, NET Grade 2, NEC (large cell or small cell),
mixed adeno-neuroendocrine carcinoma (MANEC), and
hyperplastic and neoplastic lesions, in the 2010 WHO
classification according to the grading by the Ki-67 label-
ing index [8]. However, the classification of the pancre-
atic/gastrointestinal NETs (where the research is the most
advanced) is slightly different from that of lung NETs
which are sometimes still called “carcinoid”, and the
standard pathological classification is yet to be achieved.
NETs are also clinically classified as follows: 1) func-

























Fig. 3 Survival period after diagnosis of metastatic brain tumor
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of characteristic hormonal symptoms; 2) foregut origin
(lungs/bronchus, thymus, stomach, pancreas, duodenum),
midgut origin (jejunum, ileum, appendix), and hindgut
origin (colon, rectum), depending on the site of embryo-
logical development; 3) whether or not associated with
inherited diseases (including multiple endocrine neoplasia
type 1, von Hippel-Lindau disease, neurofibromatosis type
1, and tuberous sclerosis) [8]. Therefore, the clinical and
pathological definition of NETs is still complicated.
The National Cancer Institute’s Surveillance, Epidemi-
ology, and End Results (SEER) Program (1993 to 2004)
searched all registered patients using the International
Classification of Disease (ICD) codes such as carcinoid,
neuroendocrine carcinoma, and LCNEC, and extracted
17,321 patients with NETs [9]. The incidence of NETs
among all tumors was 4.44 % in Caucasians and 6.5 % in
African Americans, and male patients were slightly pre-
dominant; the incidence increased by 37 % in Caucasians
and 40 % in African Americans compared with the stat-
istical data between 1993 and 1997 [9]. The site of onset
of NETs in Caucasian patients was the lungs/bronchus
in 31.9 %, small intestine in 17.7 %, unknown in 13.5 %,
and rectum in 12.3 %, whereas that in African American
patients was the rectum in 27 %, small intestine in 21 %,
and lungs/bronchus in 18.3 %. Thus, a slight ethnic
difference was observed [9]. Also in the percentage of
NETs against all types of tumors in each site of origin,
NETs accounted for the highest (1.42 %) in the lungs/
bronchus in Caucasian patients, whereas NETs accounted
for the highest (1.65 %) in the rectum in African American
patients [9]. The clinical pathology of pancreatic NETs has
been most intensively studied. However, pancreatic NETs
accounted for 4 % of all types of the NETs and for
approximately 0.3 % of all pancreatic cancers [9], being a
very rare disease. Regarding the metastasis of NETs to
other organs, distant metastasis was observed in 20 % to
30 % of patients at the time of diagnosis.
Using the search words of SEER [9], we extracted 302
patients with NETs who were diagnosed at our hospital
over the past 6 years. The site of onset was the lungs in
C D E F
A B
G
Fig. 4 a Chest CT scan shows a small lesion (arrow) on the mediastinum at right S2. b Sagittal contrast-enhanced T1-weighted head MRI reveals
two tumors in the pineal body and the cerebellum accompanied by obstructive hydrocephalus. c HE stain image of neuroendoscopic biopsy
tissues (original magnification, × 200). d anti-synaptophysin antibody. (Rabbit polyclonal, Cell Marque, CA, USA) stain image (original magnification,
× 200). e anti-chromogranin A antibody (Rabbit polyclonal, Dako, Glostrup, Denmark) stain image (original magnification, × 200). f Ki-67 (MIB-1,
Dako, Glostrup, Denmark) stain image (original magnification, × 200). g Bone scintigraphy shows multiple metastases to the cervical vertebrae
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103 patients (34.1 %), rectum in 37 patients (12.3 %),
and pancreas in 26 patients (8.6 %), which were almost
comparable with the site of onset in Caucasian patients,
and the number of patients with NETs in the pancreas
was higher in Japanese patients. Brain metastasis was
observed in 31 patients (10.3 %) and it was interesting
that 26 (83.9 %) of them were metastasis from the pri-
mary lung NETs. Primary brain metastasis is mainly
caused by primary lung NETs whereas pancreatic/gastro-
intestinal NETs are suggested to reach the brain as the
final distal site of metastasis via metastasis to the liver,
lymph node, lungs, or other organs.
Brain metastasis from NETs has been frequently re-
ported [2, 4–7] although standardized pathological ana-
lysis, diagnosis, and treatment have not been established.
The European Neuroendocrine Tumor Society (ENETS)
in 2012 published the consensus guidelines for the diag-
nosis and treatment of neuroendocrine tumors for each
site of onset [10]. During preparation of the guidelines,
the ENETS advisory board and experts have published
the analytical results on metastasis to other organs from
NETs [10, 11]. The description of brain, cardiac, and
ovarian metastasis in the article stated that brain metas-
tasis from primary lung NETs accounted for 45 % to
71 % of patients with the median period of 1.5 years
from the diagnosis of the primary lesion until confirm-
ation of brain metastasis [8]. Lymph node metastasis
and liver metastasis were present in 75 % and 50 % of
the patients with brain metastasis [11], respectively, which
were comparable to the results of our present study.
Approximately 1.4 % of metastatic brain tumors were
NETs, whereas the incidence of brain metastasis from
NETs was 1.5 % to 5 % [11]. The incidence of primary
lung NETs was higher in our present study and that would
be the cause of slightly higher incidence in brain metasta-
sis at 10.3 %. A report that summarized 24 patients was
the highest number of patients and only 57 patients were
reported during the 46 years between 1962 and 2007 [11].
Accumulation of 31 patients during 6 years in this study is
therefore unsurpassed in terms of analysis of brain metas-
tasis from NETs. The report of ENET [11] did not contain
a definite description of pathological findings and grading.
C D  E F
A B G  H
Fig. 5 a, b Horizontal contrast-enhanced T1-weighted head MRI shows multiple tumors with cysts in the right occipital lobe and the parietal lobe.
c HE image of the isolated parietal lobe tumor tissues (original magnification, × 200). d anti-synaptophysin antibody stain image (original magnification,
× 200). e anti-CD56 antibody (1B6, Leica, Newcastle, UK) stain image (original magnification, × 200). f anti-TTF-1 (8G7G3/1, Dako, Glostrup, Denmark)
antibody stain image (original magnification, × 200). g, h Horizontal contrast-enhanced T1-weighted head MRI after cranial irradiation therapy
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Our report may be the first to suggest that most of
the patients consist of Grade 3 LCNEC and Grade 3
small cell cancer.
To the best of our knowledge, no report described
detailed treatment and outcomes for brain metastasis in
NET patients. When limited to lung NETs, brain metas-
tasis occurs in 30 % or more of the LCNEC patients and
in 24 % of the small cell carcinoma patients [3, 12]. In
the present study, the strategy of surgery and radio-
therapy for the patients was determined based on the
symptoms, PS, and imaging findings (number of brain
metastases), and such action would be the standard
concept for metastatic brain tumors at present. On the
other hand, prophylactic cranial irradiation is also a
possible option for small cell lung cancer [3, 12, 13].
The median survival period from diagnosis of brain
metastasis was 8.1 months in the present study, and it
was not greatly different from that of brain metastasis
in all lung cancer patients [13]. Lately, various therap-
ies such as combination chemotherapy, EGFR tyrosine
kinase inhibitors (EGFR-TKI), and angiogenesis inhibitors
have become available for brain metastasis originating
from lung cancer [13, 14]. Development of optimal ther-
apy is expected in addition to surgery and radiotherapy
for brain metastasis originating from NETs based on the
accumulation of findings of new chemotherapies and
molecular targeted therapies.
Conclusion
Approximately 10 % of NET patients developed brain
metastasis at slightly longer than 1 year after diagnosis,
and metastasis originating from LCNEC or small cell
carcinoma occurred in most of them. Local recurrence
or metastasis, or metastasis to another organ were often
present at the time of diagnosis of brain metastasis, and
the treatment options for brain metastasis varied depend-
ing on the symptoms due to brain metastasis, PS, and
metastatic images. Most of the metastases were controlled
by applying active therapy to the brain lesion, but the
mean survival period was 8 months from diagnosis of
brain metastasis, mainly because of aggravation of the pri-
mary lesion or metastasis to other organs. Standardization
of clinical pathological interpretations of NETs has been
attempted in recent years, and such reports are rapidly
increasing. Nevertheless, few reports have been published
concerning the pathology of brain metastasis of NETs,
and the findings of our clinicopathological analysis of this
pathology were limited to the experience of our institu-
tion. We hope for standardization of clinical and patho-
logical interpretation of NETs and the establishment of
optimal guidelines for diagnosis and treatment of brain
metastasis originating from NETs by accumulating more
information on this disease.
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